/PKBO
PKBO Stock - Peak Bio, Inc.
Healthcare|BiotechnologyNASDAQ
$0.02+0.00%
57
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.50
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.49
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.02
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PKBO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.02 – $0.02
TARGET (TP)$0.03
STOP LOSS$0.02
RISK/REWARD1:3.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.78
52W High$0.02
52W Low$0.02
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $367,877 | N/A | $528,309 | N/A |
| Gross Profit | N/A | $367,769 | $607,572 | $528,309 | N/A |
| Gross Margin | N/A | 100.0% | N/A | 100.0% | N/A |
| Operating Income | $-1,673.558 | $-1,356.228 | $-861.797 | $-9,066,000 | $-2,350.319 |
| Net Income | $-1,676.22 | $-1,259.26 | $-905.934 | $-8,293,000 | $-2,458.288 |
| Net Margin | N/A | -0.3% | N/A | -1569.7% | N/A |
| EPS | $-0.02 | $-0.00 | $-0.74 | $-0.48 | $-0.00 |
Company Overview
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
PKBOBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.11
Q3 2024
EPS Surprise History
Q1 22
No data
Q2 22
No data
Q3 22
No data
Q3 22
No data
Q4 22
No data
Q1 23
No data
Q2 23
No data
Q3 24
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2024 | Aug 23, 2024 | — | $-0.11 | — | — |
Q4 2023 | Oct 10, 2023 | — | — | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.29 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.32 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.74 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.01 | — | — |
Q3 2022 | Aug 16, 2022 | — | $-0.07 | — | — |
Q2 2022 | May 20, 2022 | — | $-0.10 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.51 | — | — |
Q3 2021 | Sep 30, 2021 | — | $0.01 | — | — |
Latest News
Loading news...
Frequently Asked Questions about PKBO
What is PKBO's current stock price?
Peak Bio, Inc. (PKBO) is currently trading at $0.02 per share. The stock has moved +0.00% today.
What is the analyst price target for PKBO?
No analyst price targets are currently available for this stock.
What sector is Peak Bio, Inc. in?
Peak Bio, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is PKBO's market cap?
Peak Bio, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does PKBO pay dividends?
No, Peak Bio, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBIOC
Biocept, Inc.
$0.43
Mkt Cap: $0.0B
BLCM
Bellicum Pharmaceuticals, Inc.
$0.07
Mkt Cap: $0.0B
INFIQ
Infinity Pharmaceuticals, Inc.
$0.00
Mkt Cap: $0.0B
OTRK
Ontrak, Inc.
$0.33
Mkt Cap: $0.0B
PHGE
BiomX Inc.
$2.13
Mkt Cap: $0.0B
PHIO
Phio Pharmaceuticals Corp.
$1.07
Mkt Cap: $0.0B
TCBP
TC Biopharm (Holdings) Plc
$0.50
Mkt Cap: $0.0B
TFFP
TFF Pharmaceuticals, Inc.
$0.07
Mkt Cap: $0.0B
WENA
Anew Medical, Inc.
$0.73
Mkt Cap: $0.0B
XAGE
Longevity Health Holdings Inc.
$0.43
Mkt Cap: $0.0B
Explore stocks similar to PKBO for comparison